Compare LGL & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | PMN |
|---|---|---|
| Founded | 1917 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 23.5M |
| IPO Year | N/A | N/A |
| Metric | LGL | PMN |
|---|---|---|
| Price | $5.75 | $9.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $72.67 |
| AVG Volume (30 Days) | 8.7K | ★ 43.4K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 149.85 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $4,107,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.45 | $6.27 |
| 52 Week High | $9.74 | $39.75 |
| Indicator | LGL | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 89.39 |
| Support Level | $5.59 | $7.35 |
| Resistance Level | $5.99 | $9.26 |
| Average True Range (ATR) | 0.26 | 0.66 |
| MACD | -0.00 | 0.28 |
| Stochastic Oscillator | 50.00 | 99.12 |
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.